Safety and Tolerability of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed By Polatuzumab Vedotin in B-cell Non-Hodgkin Lymphoma

Key Points

• Polatuzumab vedotin shows favorable safety profiles after myeloablative conditioning and stem cell transplantation, enhancing treatment options for lymphoma patients.
• The study reports high tolerability rates among B-cell non-Hodgkin lymphoma patients undergoing this innovative treatment regimen.
• Assessment utilizing a comprehensive clinical approach highlighted the promising combination's capability to manage adverse effects effectively.
• Implications of results indicate a shift towards potentially effective therapy, requiring further trials to confirm longevity and efficacy.